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Abstract
Background: The validity of prediction models needs external validation to assess their
value beyond the original development setting.
Objective: To report the diagnostic accuracy of the European Randomized Study of
Screening for Prostate Cancer (ERSPC) risk calculator (RC)3 and RC4 in a contemporary
Dutch clinical cohort.
Design, setting, and participants: We retrospectively identified all men who underwent
prostate biopsy (PBx) in the Jeroen Bosch Hospital, The Netherlands, between 2007 and
2016. Patients were included if they met ERSPC RC requirements of age (50–80 yr),
prostate-specific antigen (PSA) (0.4–50 ng/ml), and prostate volume (10–150ml). The
probability of a positive biopsy for prostate cancer (PCa) and significant PCa (Gleason score
7 and/or higher than T2b) were calculated and compared with PBx pathology results.
Outcome measurements and statistical analysis: Evaluation was performed by calibra-
tion, discrimination, and clinical usefulness using calibration plots, area under the
receiver operating characteristic curves (AUCs), and decision curve analyses (DCAs),
respectively.
Results and limitations: A total of 2270 PBx sessions were eligible for final analysis.
Discriminative ability of RC3 (AUC) was 0.78 and 0.90 for any PCa and significant PCa,
respectively. For RC4 the calculated AUCswere 0.62 (any PCa) and 0.76 (significant PCa).
The calibration plots of RC3 showed good results for both any PCa risk and significant
PCa risk. In the repeat PBx group, RC4 tended to underestimate outcomes for PCa and
showed moderate calibration for significant PCa. DCA showed an overall net benefit
compared with PSA and digital rectal examination (DRE) alone. Limitations of this study
are its retrospective single-institution design, retrospectively assessed DRE outcomes,
no time restrictions between the first and repeat biopsy sessions, and no anterior
sampling in the repeat PBx protocol.
Conclusions: The ERSPC RCs performed well in a contemporary clinical setting. Most
pronounced in the biopsy-naive group, both RCs should be favoured over a PSA plus
DRE–based stratification in the decision whether or not to perform PBx.
Patient summary: We looked at the ability of the existing European Randomized Study
of Screening for Prostate Cancer risk calculator (RC), using different clinical data to
predict the presence of prostate cancer in Dutchmen. The RC performedwell and should
be favoured in the decision of whether or not to perform prostate biopsies over the
conventional diagnostic pathway.
# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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* Corresponding author. Jeroen Bosch Hospital, PO Box 90153 5200 ME, ‘s-Hertogenbosch,
The Netherlands. Tel. +31 73 5532407; Fax: +31 73 5532373.
E-mail address: m.gayet@jbz.nl (M. Gayet).
http://dx.doi.org/10.1016/j.euf.2016.07.007
2405-4569/# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
1. Introduction
An estimated 1.1 million men worldwide were diagnosed
with prostate cancer (PCa) in 2012, accounting for 15% of
cancers in men, with 70% of them in more developed
countries. PCa accounts for 6.6% of the total male cancer
mortality. Incidence rates diverge, mainly because of serum
prostate-specific antigen (PSA) testing [1]. First described in
1979, PSA made large-scale screening for PCa feasible.
However, determination of serum PSA for diagnostic
purposes lacks accuracy, with 15–25% false negatives and
60% false positives [2,3]. The likelihood of the presence of
PCa is therefore preferably estimated by using additional
clinical factors, such as digital rectal examination (DRE) and
prostate volume (PV).
Although it has been shown that PCa-specific mortality
can be reduced by 20% with PSA-based screening, popula-
tion-based screening programs are not yet acceptable
because of the high number needed to screen and the high
number needed to treat to avoid one PCa death. More
importantly, PSA-based screening results in a considerable
number of unnecessary prostate biopsies (PBx) with
potentially serious adverse events and leads to considerable
overdiagnosis [4,5]. To achieve higher diagnostic accuracy,
several nomograms and artificial neural networks (ANNs)
have been developed to predict the outcome of PBx. These
models have been shown to improve diagnostic accuracy
compared with PSA alone [6,7]. However, it is necessary to
assess the validity of these models outside the original
development setting. Unfortunately, many of the published
nomograms and ANNs lack external validation.
In 2006, different risk calculators (RCs) based on the
Dutch section of the European Randomized Study of
Screening for Prostate Cancer (ERSPC) were developed using
data ofmenwith a purely PSA-driven biopsy indication and a
random transrectal ultrasound (TRUS)-guided sextant biopsy
scheme [8]. ERSPC RC1 and RC2 are for patient use; RC3 (plus
DRE), RC4 (plus DRE), RC5, and RC6 are for use by health care
professionals at different stages of the testing process.
Several external validation studies have been performed for
these RCs. In both European and non-European cohorts, the
accuracy of prediction of positive PBx in biopsy-naive or
previously biopsied men using the ERSPC RC3 or RC4 was
assessed, showing area under the curve (AUC) values in the
range of 0.71–0.88 [9–12]. Until now, ERSPC RC3 plus DRE
and RC4 plus DRE were externally validated using an
extended biopsy scheme instead of a sextant biopsy scheme
in both a Swiss and Irish cohort, with AUC for PCa and
significant PCa of 0.66–0.77 and 0.85, respectively, and
showing sufficient to good calibration [13,14].
The aim of this study was to assess the accuracy of the
ERSPC RC3 and RC4 in a contemporary Dutch clinical cohort
for which biopsy indications and number of biopsies
differed from the development cohort.
2. Material and methods
2.1. Study population
We retrospectively identified all men who underwent PBx due to a
clinical suspicion of PCa between January 2007 and December 2015 at
the Jeroen Bosch Hospital. In our institution PBx was generally
performed in patients with a serum PSA level 3.0–4.0 mg/l and/or an
abnormal DRE. A standardised 12-core biopsy protocol consisting of two
biopsies of each base, mid-gland, and apex in the peripheral zone of the
prostatewas performed, with additional cores takenwhen needed (eg, in
case of hypoechogenic lesions). We examined patient files and obtained
relevant clinical and pathologic data of each patient. Patients were
included in our study if PCa risk prediction was considered relevant and
possible, thus patients aged 50–80 yr with a PSA level between 0.4 and
50 mg/l, PV between 10 and 150 ml, and no previous positive PBx (ie,
under active surveillance). Patients with a history of PCa were excluded.
For our analyses, we retrospectively converted the descriptively
documented DRE findings in our cohort to clinical T stages.
The patient database was blinded by PCa diagnosis and sent to one of
the ERSPC RC designers (M.J.R.) for risk outcome calculations. Probabilities
of detection of PCa and significant prostate PCa (Gleason score7 and/or T
stage higher than T2b) were calculated for each patient individually using
two ERSPC RCs (www.prostatecancer-riskcalculator.com). RC3 was used
to calculate probabilities in biopsy-naive patients; RC4 was used for
patients with previous negative biopsy sessions undergoing a repeat PBx
(Supplementary Table 1). The calculated probabilities were subsequently
compared with the actual biopsy results for the entire cohort.
2.2. Statistics
Differences between clinical and pathologic variables in the studied
cohort were assessed using the chi-square test for categorical variables
and theMann-Whitney U test for continuous variables. The performance
of both RCs in the clinical setting was assessed by discrimination,
calibration, and clinical usefulness.
Discrimination, that is, predictive accuracy, was quantified using the
receiver operating characteristics derived AUC. Calibration refers to the
agreement between observed and predicted outcomeswith the extent of
risk of over- or underestimation of the RCs evaluated graphically using
calibration plots [15].
Clinical usefulness of the RCs was evaluated by decision curve
analyses (DCAs) as described previously by Vickers and Elkin and by
Steyerberg et al [16,17]. DCAs determine the value (net benefit) of a
prediction model by examining the theoretical relationship between the
threshold probability of an event (eg, PCa at biopsy) and the relative
value of false-positive and false-negative results. We compared the RC
model with a PSA plus DRE–based model, also developed on original
ERSPC data. We also assessed the theoretical number of (significant)
cases of PCa missed, numbers of biopsies saved, and number of Gleason
score 6 PCa diagnoses saved at different RC thresholds.
Statistical analyses were performed using SPSS v23.0 (IBM Corp,
Armonk, NY, USA) and R v3.2.5 (R Foundation for Statistical Computing,
Vienna, Austria). A p < 0.05 was considered to indicate statistical
significance in all analyses.
3. Results
We identified 2862 prostate biopsy sessions in 2124 men.
Overall, 426 biopsy sessions were omitted due to the
predefined inclusion criteria. In 166 biopsy sessions (<6%),
data were incomplete (PSA, n = 2; DRE findings, n = 123;
TRUS PV, n = 27; TRUS findings, n = 40) and excluded from
further analyses. As a result, 2270 prostate biopsy sessions
(79.3%) in 1812 different men were eligible for final
analysis: 73.0% biopsy-naive men and 27.0% men with a
prior negative PBx.
PCa and significant PCawere detected in 44.1% and 20.3%
of the biopsy-naive men (n = 1658). Men with PCa and
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significant PCa were significantly older compared with men
with no cancer detected, had higher PSA levels, lower PVs,
and were more likely to have an abnormal DRE and TRUS
(Table 1). In the previously biopsied men (n = 612), 25.8%
and 7.0% ofmenwere diagnosedwith PCa or significant PCa,
respectively. Men with PCa and significant PCa detected
were significantly older and had lower PVs compared with
men in whom no PCa was detected. Their PSA level did not
differ from men with no PCa detected. Only men with
significant PCa disease were more likely to have an
abnormal DRE or TRUS (Table 2).
AUC for the discrimination of (significant) PCa in the
biopsy-naive group (RC3) was 0.78 (95% confidence interval
[CI], 0.76–9.80) for PCa and 0.91 (95% CI, 0.89–0.92) for
significant PCa. The discriminative ability of the RC4 in the
repeat PBx group was lower with an AUC of 0.62 (95% CI,
0.56–0.67) for any PCa and 0.74 (95% CI, 0.66–0.81) for
significant PCa.
In the biopsy-naive group, mean predicted outcomes
were close to the observed outcomes of PCa and significant
PCa (Fig. 1). The calibration plots showed good results for
both outcomes over the whole prediction range, reflected in
the calibration-in-the-large of 0.18 (95% CI, 0.08–0.31) and a
calibration slope of 0.92 (95% CI, 0.81–1.02) for PCa and
calibration-in-the-large of0.15 (95% CI,0.30 to 0.01) and
a calibration slope of 1.25 (95% CI, 1.12–1.38) for significant
PCa (Fig. 1).
In the repeat PBx group, the RC tended to underestimate
outcomes for PCa and showed moderate calibration for
significant PCa in the low-risk range between 0 and
0.15. Calibration-in-the-large was 0.49 (95% CI, 0.31–0.67)
and 0.31 (95% CI, 0.01–0.62) with a calibration slope of
0.64 (95% CI, 0.37–0.90) and 0.80 (95% CI, 0.55–1.06) for PCa
and significant PCa, respectively (Fig. 1).
The net benefit in the biopsy-naive group, assessed with
DCA, was highest for the RC over the whole probability
range, as compared with a PSA plus DRE–based strategy for
PCa and for significant PCa (Fig. 2). A threshold algorithm
(20.0% for PCa at biopsy or 12.5–20.0% for PCa at biopsy
with >4% for significant PCa at biopsy) presented by the
ERSPC RC developers (www.prostatecancer-riskcalculator.
com) would result in 20% (n = 337) fewer biopsies in our
cohort. As a consequence we would miss 7% (n = 52) of the
PCa of which 12% (n = 6) is significant PCa. The diagnosis of
Gleason score 6 PCa would be spared in 46 men (Supple-
mentary Table 2).
In the repeat PBx group, DCA provided a net benefit for
the RC in the threshold probability range from 20% to 35%
but also a net harm compared with the ‘‘biopsy all’’ line at
the lower risk thresholds for PCa. For significant PCa, the RC
provided a small net benefit in the lowest threshold
probability range compared with a PSA plus DRE–based
strategy (Fig. 2). The threshold algorithm (20.0% for PCa at
biopsy or 12.5–20.0% for PCa at biopsy with >3% for
significant PCa at biopsy) presented by the ERSPC RC
developers would result in 47% (n = 285) fewer biopsies
with 35% (n = 55) of the PCa missed of which 18% (n = 10) is
significant PCa. The diagnosis of Gleason score 6 PCa would
be spared in 45 men (Supplementary Table 3).
4. Discussion
The ERSPC RCs quantify the chance of finding PCa on sextant
biopsy by translating the presence or absence of abnormal
Table 1 – Clinical and pathologic characteristics of the biopsy-naive patient cohort
Variable Total cohort Positive biopsy Negative biopsy
All PCa, p value Significant PCa, p value
No. of patients, n (% total cohort) 1658 (100) 732 (44.1) 337 (20.3) 926 (59.1)
Age, yr, median (IQR) 64 (60–69) 66 (62–71), <0.001 68 (63–73), <0.001 64 (59–68)
Age, yr, n (%)
50 to <60 369 (22.3) 128 (17.5) 47 (13.9) 241 (26.0)
60 to <70 904 (54.5) 377 (51.5) 148 (44.0) 527 (56.9)
70 385 (23.2) 227 (31.0) 142 (42.1) 158 (17.1)
PSA level, mg/l, median (IQR) 7.6 (5.9–11.0) 8.6 (6.2–14.0), <0.001 11.0 (7.6–20.0), <0.001 7.1 (5.6–9.4)
PSA ranges, mg/l, n (%)
<1 6 (0.4) 1 (0.1) 0 (0.0) 5 (0.5)
1 to <4.0 91 (5.5) 33 (4.5) 9 (2.7) 58 (7.3)
4.0–10.0 1082 (65.2) 416 (56.9) 135 (40.0) 666 (70.9)
10.0 479 (28.9) 282 (38.5) 193 (57.3) 197 (21.3)
DRE findings, n (%)
Normal 1198 (72.3) 386 (52.7) 73 (21.7) 812 (87.7)
Abnormal 460 (27.7) 346 (47.3), <0.001 264 (78.3), <0.001 114 (12.3)
TRUS prostate volume, ml, median (IQR) 40.0 (30.0–55.0) 35.0 (28.0–46.0), <0.001 33.0 (27.0–44.0), <0.001 46.0 (35.0–60.0)
TRUS findings, n (%)
Normal 1267 (76.4) 461 (63.0) 147 (43.6) 806 (87.0)
Abnormal 391 (23.6) 271 (37.0), <0.001 190 (56.4), <0.001 120 (13.0)
Total cores taken at biopsy, n (%)
<12 24 (1.4) 13 (1.8) 7 (2.1) 11 (1.2)
12 1379 (83.2) 609 (83.2) 269 (79.8) 770 (83.2)
>12 255 (15.4) 110 (15.0), 0.504 61 (18.1), 0.653 145 (15.7)
DRE = digital rectal examination; IQR = interquartile range; PCa = prostate cancer; PSA = prostate-specific antigen; TRUS = transrectal ultrasound.
The p values in bold indicate a statistically significant difference between two groups (positive biopsy; all PCa vs negative biopsy and positive biopsy;
significant PCa vs negative biopsy).
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findings into a probability. PBx is recommended by the
ERSPC RC developers at a probability threshold 20% for
PCa and can be considered in the 12.5–20.0% threshold
range for PCa, especially if significant PCa probabilities
reach >4% or >3% for the RC3 and RC4, respectively. Both
threshold groups were assessed using DCA and showed
good to moderate clinical benefit in biopsy-naive and
previously biopsied men, respectively. The proposed
threshold algorithm for biopsy-naive men (20.0% for
PCa or12.5% for PCa and>4% for significant PCa) seems to
be acceptable. Only 6 significant cases of PCa (2%) are being
missed as a result of saving 337 biopsy sessions (20%).
However, the threshold algorithm for previously biopsied
men (20.0% for PCa or 12.5% for PCa and >3% for
significant PCa) is not optimal for our cohort. With
285 fewer biopsies (47%), 10 significant cases of PCa
(23%) are being missed. A threshold algorithm10% for PCa
or >2% for significant PCa seems optimal as only 1 signifi-
cant PCa (2%) is being missed and 131 biopsy sessions (21%)
are still saved (Supplementary Table 3).
AUCs of the original sextant biopsy scheme ERSPC data
are 0.79 and 0.86 for RC3 and 0.68 and 0.80 for RC4 for all
PCa and significant PCa, respectively [18]. In the present
study, diagnostic accuracy reaches that of the original
ERSPC report, especially for RC3. This is in contrast to
previous external validation reports of these RCs that
reported various, mostly lower diagnostic accuracy results
[9–12]. This may be partially the result of ethnic similarities
and (significant) PCa prevalence resemblance between the
original development and validation cohort [18]. Previous
validation studies assessed a combined AUC for both RC3
and RC4, whereas our study demonstrates that accuracy of
both RCs differed substantially. Consequently, a subopti-
mally performing RC canmask the potentially high accuracy
of another RC.
In comparison with the new RC3 plus DRE and RC4 plus
DRE, our present study also demonstrates higher diagnostic
accuracy [13,14]. One major reason for this may be the use
of TRUS-based PV measurements. Predictions of PCa using
TRUS-based PV data have been shown to outperform
predictions using DRE-based data because PV was demon-
strated to be an important predictor in the detection of PCa
[18,19]. Redistribution of TRUS-based volume in DRE-stated
categories could therefore have negatively influenced
Table 2 – Clinical and pathologic characteristics of the repeat prostate biopsy patient cohort
Variable Total cohort Positive biopsy Negative biopsy
All PCa, p value Significant PCa, p value
No. of patients, n (% total cohort) 612 (100) 158 (25.8) 43 (7.0) 454 (74.2)
Age, yr, median (IQR) 65 (61–69) 66 (62–71), 0.002 69 (64–74), <0.001 64 (60–69)
Age, yr, n (% col)
50 to <60 122 (19.9) 24 (15.2) 3 (7.0) 98 (21.6)
60 to <70 347 (56.7) 83 (52.5) 19 (44.2) 264 (58.1)
70 143 (23.4) 51 (32.3) 21 (48.8) 92 (20.3)
Repeat biopsy session
First 440 (71.9) 122 (77.2) 32 (74.4) 318 (70.0)
Second 121 (19.8) 26 (16.5) 10 (23.3) 95 (20.9)
Third 34 (5.6) 7 (4.4) 1 (2.3) 27 (5.9)
Fourth or more 17 (2.9) 3 (1.9) 0 14 (3.1)
Time interval, mo*, median (IQR) 16 (7–39) 16 (7–40) 10 (32–51) 16 (7–39)
Time interval, yr*, n (%)
1 yr 257 (42.3) 65 (41.1) 12 (27.9) 192 (42.8)
>1 to 2 yr 116 (19.1) 31 (19.6) 6 (14.0) 85 (18.9)
>2 to 3 yr 72 (11.9) 20 (12.7) 8 (18.6) 52 (11.6)
>3 yr 162 (26.7) 42 (26.6) 17 (39.5) 120 (26.7)
PSA level, mg/l, median (IQR) 9.6 (7.4–14.0) 8.9 (7.2–14.1), 0.369 10.0 (7.3–18.0), 0.323 9.6 (7.5–14.0)
PSA ranges, mg/l, n (%)
<1 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.2)
1 to <4.0 7 (1.1) 1 (0.6) 1 (2.3) 6 (1.3)
4.0–10.0 327 (53.4) 91 (57.6) 20 (46.5) 236 (52.0)
10.0 277 (45.3) 66 (41.8) 22 (51.2) 211 (46.5)
DRE findings, n (%)
Normal 431 (70.4) 107 (67.7) 16 (37.2) 324 (71.4)
Abnormal 181 (29.6) 51 (32.3), 0.388 27 (62.8), <0.001 130 (28.6)
TRUS prostate volume, ml, median (IQR) 48.0 (35.3–66.0) 43.0 (30.0–58.3), <0.001 43.0 (30.0–52.0), 0.006 50.0 (38.0–68.0)
TRUS findings, n (%)
Normal 479 (78.3) 124 (78.5) 28 (65.1) 355 (78.2)
Abnormal 133 (21.7) 34 (21.5), 0.940 15 (34.9), 0.051 99 (21.8)
Total cores taken at biopsy, n (%)
<12 12 (2.0) 3 (1.9) 1 (2.3) 9 (2.0)
12 391 (63.9) 93 (58.9) 26 (60.5) 298 (65.5)
>12 209 (34.1) 62 (39.2), 0.125 16 (37.2), 0.414 147 (32.5)
DRE = digital rectal examination; IQR = interquartile range; PCa = prostate cancer; PSA = prostate-specific antigen; TRUS = transrectal ultrasound.
The p values in bold indicate a statistically significant difference between two groups (positive biopsy; all PCa vs negative biopsy and positive biopsy;
significant PCa vs negative biopsy).
* Time interval in months/years: Time in months/years between previous biopsy session and the repeat biopsy session used for the analysis.
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predictive accuracy in the external ERSPC validation by
Poyet et al [13]. Trottier et al also demonstrated in their
external validation that, on multivariate analysis, TRUS-
measured PV and TRUS lesion were the most important risk
model predictors for a positive (significant) PCa diagnosis at
biopsy [12].
In this study, calibration plots showed good outcomes for
biopsy-naive men. In the repeat PBx group, mean predicted
and mean observed outcome disagreed and tended to
underestimate the PBx results. However, there was
moderate calibration for significant PCa in the clinically
relevant low-risk range between 0 and 0.15. One of the
contributing components for this moderate calibration (and
the underestimation of PBx results) could be the fact that
men with a previous negative PBx were a higher risk cohort
compared with the cohort within the ERSPC, in which every
man with PSA 3.0 ng/ml at repeat screening was biopsied
again. In addition, RC4 is developed using a cohort with at
least 4 yr between initial and repeat PBx. In our analysis,
there was no minimal maintained time range between
first and repeat PBx with a median time of 16.5 mo (range:
7.0–39.0 mo) between both biopsy sessions.
PSA testing and screening remain a subject of debate. On
the one hand, evidence indicates that it reduces PCa
mortality, but on the other hand, there is a risk of
overdiagnosis and overtreatment. Offering PSA in an
organised way and combining it with other relevant risk
factors regarding PCa will most likely result in a more
beneficial harm–benefit ratio [20–22]. Our study confirms
that individual risk assessment using a multivariable
prediction model should be used in the consideration
whether or not to perform PBx.
Limitations of this study are its retrospective single-
institution design. Because of the lack of documentation of
[(Fig._1)TD$FIG]
Fig. 1 – Calibration plots for the European Randomised Study of Screening for Prostate Cancer risk calculator (RC) 3 (left) and RC4 (right)
demonstrating the agreement between observed and predicted probabilities for prostate cancer (PCa) at biopsy (upper figures) or significant PCa at
biopsy (lower figures). The ideal plot is showed with a dashed line through the origin. The solid line reflects the relation between observed and
predicted probability with quintiles of grouped patients shown by triangles. The numbers of patients with and without the condition are shown as
spikes along the x-axis.
PCa = prostate cancer; RC = risk calculator.
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T-stage DRE, DRE was retrospectively converted to T stage,
which could have created biases in either direction
(understaging or overstaging). Also, as mentioned earlier,
there was no minimal maintained time range between the
first and repeat biopsy sessions. However, most early cases
of PCa (T1–T2) have an indolent course for 10–15 yr
[23]. The difference in time range between the first and
repeat biopsy sessions is unlikely to have influenced our
results. Lastly, in repeat PBx sessions, the initial sampling
protocol and not an extended sampling protocol including
anterior PBx was used.
With new biomarkers and imaging techniques available,
the field of diagnosis of PCa is changing. In the last 2 yr,
several groups combined new biomarkers and clinical
features into prediction models and compared accuracy of
these models with ERSPC or Prostate Cancer Prevention
Trial RCs, and they concluded that diagnostic accuracy
increased compared with the conventional RCs [24–27].
ERSPC RC4 was also used to predict the outcome of
multiparametric magnetic resonance imaging (mpMRI) by
Alberts et al [28]. Patient selection using a RC can avoid half
of the mpMRIs after a prior negative biopsy.
Hence, for future perspectives, it would be of interest to
develop and validate RCs that include new diagnostic
means, such as biomarkers, or develop RCs that predict
outcomes of mpMRI, for example. Such an individualized
approach for PCa detection could reduce the adverse effects
of our diagnostic approaches and/or treatments.
5. Conclusions
In our external validation of the screening-based ERSPC RCs
for both biopsy-naive and previously biopsied men, both
RCs showed net benefit in our clinical setting compared
with a PSA plus DRE–based strategy that was most
pronounced in the biopsy-naive group. Multivariate risk
stratification should be favoured in the decision whether or
not to perform PBx.
[(Fig._2)TD$FIG]
Fig. 2 – Decision curve analysis demonstrating the net benefit of the risk calculator (blue line) and prostate-specific antigen plus digital rectal
examination (red line) for prostate cancer (PCa) at biopsy (upper curves) or significant PCa at biopsy (lower curves).
DRE = digital rectal examination; ESRPC = European Randomised Study of Screening for Prostate Cancer; PCa = prostate cancer; PSA = prostate-specific
antigen; RC = risk calculator.
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